Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2010

View Archived Issues

Ramucirumab is tolerated in patients with advanced HCC in ongoing phase II trial

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Scientists reveal predictors of adverse events associated with losartan therapy for heart failure

Novel ACAT-1 inhibitors presented by Galderma

Scientists create Maraba MG1 virus strain with increased tumor-selective potency

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Daiichi Sankyo identifies new inhibitors of HSP 90 ATPase activity

Ligand Pharmaceuticals and Proximagen collaborate on chemokine CXCR4 receptor target

Trial of TT-223/GLP-1 analogue combination in type 2 diabetes does not meet endpoints

RaQualia Pharma claims new motilin receptor agonists

Vantia identifies new vasopressin V1A receptor antagonists

LigoCyte begins phase I trial of bivalent intramuscular norovirus vaccine

Novel COX-1 inhibitors described by Japanese scientists

ImmunoCellular Therapeutics begins phase II glioblastoma study of ICT-107

Ablynx reports follow-up data from phase I study of ALX-0141

Faron Pharma advances FP-1201 into second part of trial in acute lung injury

Novartis Europharm withdraws Rasival MAA for essential hypertension

Phase III Northera trial meets endpoint in neurogenic orthostatic hypotension

Icagen suspends enrollment in photosensitivity study of ICA-105665

Boehringer Ingelheim begins phase III afatinib trial in breast cancer

EMA updates nevirapine label for patients with HIV-1 infection

Synvisc is approved in Japan for osteoarthritis of the knee

Hybrigenics reports phase IIa data on inecalcitol/docetaxel combination in prostate cancer

Endo Pharma completes tender offer for Penwest Pharma shares

SCH-527123 is safe and efficacious in phase II trial in COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...